MyoKardia, Inc. (MYOK) CEO Anastasios Gianakakos Sells 4,300 Shares of Stock
MyoKardia, Inc. (NASDAQ:MYOK) CEO Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $40.23, for a total transaction of $172,989.00. Following the completion of the transaction, the chief executive officer now directly owns 513,417 shares in the company, valued at $20,654,765.91. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Anastasios Gianakakos also recently made the following trade(s):
- On Wednesday, October 4th, Anastasios Gianakakos sold 4,300 shares of MyoKardia stock. The stock was sold at an average price of $40.86, for a total transaction of $175,698.00.
- On Tuesday, September 5th, Anastasios Gianakakos sold 4,300 shares of MyoKardia stock. The stock was sold at an average price of $43.02, for a total transaction of $184,986.00.
MyoKardia, Inc. (MYOK) traded down $2.40 during midday trading on Thursday, reaching $37.25. 193,321 shares of the company’s stock traded hands, compared to its average volume of 371,387. MyoKardia, Inc. has a 1-year low of $10.55 and a 1-year high of $49.55.
MyoKardia (NASDAQ:MYOK) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.42). The business had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. MyoKardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The company’s revenue was up 58.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) earnings per share. equities research analysts anticipate that MyoKardia, Inc. will post -1.62 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/09/myokardia-inc-myok-ceo-anastasios-gianakakos-sells-4300-shares-of-stock.html.
A number of equities analysts recently weighed in on MYOK shares. BidaskClub raised shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Zacks Investment Research downgraded shares of MyoKardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. BMO Capital Markets reissued an “outperform” rating and issued a $65.00 price target (up from $45.00) on shares of MyoKardia in a report on Monday, August 21st. Cowen and Company boosted their price target on shares of MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a report on Monday, August 7th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $48.00 price target (up from $31.00) on shares of MyoKardia in a report on Monday, August 7th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $55.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in MyoKardia during the third quarter valued at about $202,000. TD Asset Management Inc. purchased a new stake in MyoKardia during the third quarter valued at about $364,000. Nationwide Fund Advisors lifted its holdings in MyoKardia by 36.3% during the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 2,591 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in MyoKardia during the first quarter valued at about $136,000. Finally, Alliancebernstein L.P. purchased a new stake in MyoKardia during the second quarter valued at about $148,000. 43.67% of the stock is currently owned by institutional investors and hedge funds.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Stock Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related stocks with our FREE daily email newsletter.